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inﬂammation.3 Fukui et al.4 also reported that serum
bilirubin levels were associated with microalbuminuria and
subclinical atherosclerosis in patients with type 2 diabetes.
This letter by Zelle et al.1 further supported the relationship
between serum bilirubin and diabetic nephropathy in a
case–control study.
In the letter regarding the paper by Fukui et al.,4 Kassimatis
and Moutzouris5 claimed that it was unwarranted to discuss the
potential preventive and therapeutic application of bilirubin
or its diagnostic utility as a new risk factor for diabetic
nephropathy.5 In fact, these association studies do not
necessarily implicate the causative role of bilirubin in the
development of diabetic nephropathy. Therefore, we investi-
gated whether bilirubin may protect against diabetic nephro-
pathy in experimental animals in our article.2
Prospective studies are needed to conﬁrm its diagnostic
utility as a risk factor for diabetic nephropathy. In addition,
we agree that further intervention studies are needed to
explore the possibilities of compounds with similar properties
to bilirubin, which may represent a new class of therapeutic
agents that could protect against the development of diabetic
nephropathy.
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Circulating angiopoietin-1 could
be confounded by ex vivo
platelet activation
To the Editor: Reed et al.1 recently reported the relationship
between vascular endothelial growth factor (VEGF), angio-
poietin-1 (Ang-1), angiopoietin-2 (Ang-2), and renal as well
as cardiovascular disease progression in patients with
autosomal dominant polycystic kidney disease. Ang-1 and
Ang-2 are antagonistic ligands of their common receptor
Tie2. Unlike Ang-2, which is stored in endothelial cells, Ang-1
is not exclusively expressed by the vasculature; a high amount
of Ang-1 is also found in platelets. Thus, falsely high Ang-1
serum levels may result from ex vivo activation of platelets
upon clotting in serum tubes.2 The same is probably true
for vascular endothelial growth factor.3
Reed et al. found in the autosomal dominant polycystic
kidney disease population slightly elevated Ang-2 and
vascular endothelial growth factor (2–3 fold) serum levels
compared with those earlier reported in healthy individuals.
In contrast, mean Ang-1 levels in autosomal dominant
polycystic kidney disease patients were 35.52±21.03 ng/ml,
which is more than 20 times higher than the levels we and
others repeatedly detected in plasma from healthy subjects.2
However, we had earlier published similar falsely high Ang-1
levels in patients’ sera,4 unaware of the ex vivo release out
of platelets.
As Reed et al.1 performed all measurements in patients’
sera, one might question the validity and biological relevance
behind these ﬁndings (in particular the Ang-1/Ang-2 ratio).
In summary, it is possible that their results are confounded
by platelet-derived Ang-1.
A reliable way to quantify Ang-1 in a compartment-
speciﬁc way (i.e., the true circulatory fraction) would be
highly desirable for the design of future studies.
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The Authors Reply: We thank Drs David and Ku¨mpers1 for
their interest in our recent Kidney International publication.2
They point out that as angiopoietin-1 (Ang-1) is also found
in platelets, serum levels of Ang-1 may be falsely high due
to platelet activation. In our study, the most signiﬁcant
associations were between serum vascular endothelial growth
factor (VEGF) level with renal and cardiac structure (left
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